FDA D.I.S.C.O. Burst Edition: FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer
0:00
3:00
Listen to a soundcast of the September 17, 2021 FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer.
More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Don't miss an episode of “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” and subscribe to it in the GetPodcast app.